|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9332
|
|
pubmed:dateCreated |
2002-9-20
|
|
pubmed:abstractText |
Despite the introduction of the parenteral iron chelator desferrioxamine more than 30 years ago, 50% of patients with thalassaemia major die before the age of 35 years, predominantly from iron-induced heart failure. The only alternative treatment is oral deferiprone, but its long-term efficacy on myocardial iron concentrations is unknown.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
17
|
|
pubmed:volume |
360
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
516-20
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12241655-Administration, Oral,
pubmed-meshheading:12241655-Adult,
pubmed-meshheading:12241655-Deferoxamine,
pubmed-meshheading:12241655-Echocardiography,
pubmed-meshheading:12241655-Female,
pubmed-meshheading:12241655-Humans,
pubmed-meshheading:12241655-Injections, Subcutaneous,
pubmed-meshheading:12241655-Iron,
pubmed-meshheading:12241655-Iron Chelating Agents,
pubmed-meshheading:12241655-Male,
pubmed-meshheading:12241655-Myocardium,
pubmed-meshheading:12241655-Pyridones,
pubmed-meshheading:12241655-Ventricular Function,
pubmed-meshheading:12241655-beta-Thalassemia
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.
|
|
pubmed:affiliation |
Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London SW3 6NP, UK.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
